Treatment outcome at the pediatric stem cell transplantation center in Syria: A single‐center experience

• Published in: Pediatric transplantation Vol. 28; no. 5; pp. e14789 - n/a
• Main Authors: khudari, Rawan Al, Doba, Dalal, Esmandar, Amjad, Kheder, Maged
• Format: Journal Article
• Language: English
• Published: Denmark Wiley Subscription Services, Inc 01.08.2024
• Subjects: Adolescent; allogeneic bone marrow transplantation; autologous bone marrow transplantation; Child; Child, Preschool; Female; Hematopoietic Stem Cell Transplantation; Hematopoietic stem cells; Humans; Infant; Male; Malignancy; Medical records; Patients; pediatric; Pediatrics; Retrospective Studies; Stem cell transplantation; Syria; Treatment Outcome; Syria; hematopoietic stem cell transplantation; allogeneic bone marrow transplantation; autologous bone marrow transplantation; pediatric
• ISSN: 1397-3142; 1399-3046
• DOI: 10.1111/petr.14789

Background Hematopoietic stem cell transplantation (HSCT) is a therapeutic approach known for its high success rates in treating various hematologic malignancies, hemoglobinopathies, immune deficiencies, and other disorders. Notably, pediatric HSCT commenced in Syria in 2021 amidst the prevailing crisis. This study aims to assess the demographic and clinical profiles of pediatric patients who underwent stem cell transplantation and to analyze treatment outcomes at Syria's inaugural pediatric HSCT center. Methods This study is a single‐center retrospective analysis of 25 pediatric patients who underwent HSCT underage of 14 years in the National Stem Cell Center (HAYAT) in Damascus within the period 2021–2023. The databases were created based on data that were collected from patient medical records. Results In autologous patients, transplant‐related mortality (TRM) was 0%, with 4 (57%) experiencing disease relapse, resulting in the death of one patient. Additionally, 3 (42.8%) of patients remain alive under second‐line management. The overall survival rate was 6 (85.7%), and the disease‐free survival rate was 16 (88%). In allogeneic patients, TRM was 5.5% (1/18). One allogeneic patient experienced disease relapse and subsequently died. The overall survival rate and disease‐free survival rate were 16 (88%). Conclusions The objective of this study was to assess the outcomes of pediatric HSCT patients who have undergone transplantation thus far. Given the recent initiation of pediatric stem cell transplantation in Syria, our dataset provides a basis for comparison with international hematopoietic stem cell transplantation centers regarding treatment complications and outcomes, notwithstanding the challenges and crises faced within our country. In autologous patients, transplant‐related mortality (TRM) was 0%, with 4 (57%) experiencing disease relapse, resulting in the death of one patient. Additionally, 3 (42.8%) of patients remain alive under second‐line management. The overall survival rate was 6 (85.7%), and the disease‐free survival rate was 16 (88%). In allogeneic patients, TRM was 5.5% (1/18). One allogeneic patient experienced disease relapse and subsequently died. The overall survival rate and disease‐free survival rate were 16 (88%). The objective of this study was to assess the outcomes of pediatric hematopoietic stem cell transplantation (HSCT) patients who have undergone transplantation thus far.